4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Decreased by SG Americas Securities LLC

SG Americas Securities LLC lessened its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) by 59.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,631 shares of the company’s stock after selling 12,606 shares during the quarter. SG Americas Securities LLC’s holdings in 4D Molecular Therapeutics were worth $192,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its holdings in shares of 4D Molecular Therapeutics by 167.9% in the third quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock valued at $58,000 after purchasing an additional 4,500 shares in the last quarter. Barclays PLC raised its position in 4D Molecular Therapeutics by 18.3% during the third quarter. Barclays PLC now owns 11,376 shares of the company’s stock valued at $91,000 after buying an additional 1,760 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in 4D Molecular Therapeutics by 38.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,790 shares of the company’s stock worth $110,000 after acquiring an additional 4,415 shares in the last quarter. Wetherby Asset Management Inc. purchased a new stake in 4D Molecular Therapeutics in the 1st quarter worth about $239,000. Finally, MetLife Investment Management LLC boosted its position in 4D Molecular Therapeutics by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 17,379 shares of the company’s stock worth $263,000 after acquiring an additional 6,197 shares during the period. Institutional investors and hedge funds own 79.94% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on FDMT shares. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 16th. SVB Securities decreased their target price on shares of 4D Molecular Therapeutics from $14.00 to $13.00 and set a “market perform” rating for the company in a research note on Thursday, April 13th. BMO Capital Markets started coverage on shares of 4D Molecular Therapeutics in a research note on Monday, January 30th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, SVB Leerink reduced their price objective on 4D Molecular Therapeutics from $15.00 to $14.00 and set a “market perform” rating for the company in a research report on Monday, February 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.13.

4D Molecular Therapeutics Stock Down 4.2 %

Shares of FDMT opened at $16.90 on Friday. The firm has a market cap of $544.11 million, a price-to-earnings ratio of -5.09 and a beta of 2.51. The company’s fifty day moving average is $17.56 and its 200-day moving average is $18.69. 4D Molecular Therapeutics, Inc. has a 12 month low of $5.32 and a 12 month high of $26.49.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) last issued its quarterly earnings data on Wednesday, March 15th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). 4D Molecular Therapeutics had a negative return on equity of 40.90% and a negative net margin of 3,436.51%. The business had revenue of $1.25 million during the quarter, compared to the consensus estimate of $4.97 million. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.43 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO David Kirn sold 17,997 shares of the business’s stock in a transaction that occurred on Tuesday, February 21st. The stock was sold at an average price of $20.96, for a total value of $377,217.12. Following the completion of the sale, the chief executive officer now directly owns 1,875,602 shares in the company, valued at approximately $39,312,617.92. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO David Kirn sold 17,997 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, February 21st. The shares were sold at an average price of $20.96, for a total value of $377,217.12. Following the transaction, the chief executive officer now owns 1,875,602 shares in the company, valued at approximately $39,312,617.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Global Investors Lp Viking bought 850,000 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were purchased at an average cost of $16.00 per share, with a total value of $13,600,000.00. Following the transaction, the insider now owns 4,787,914 shares in the company, valued at $76,606,624. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 28,995 shares of company stock valued at $595,854. Insiders own 10.70% of the company’s stock.

About 4D Molecular Therapeutics

(Get Rating)

4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.